Therapeutic option for patients with non-squamous NSCLC (smokers vs non-smokers)

Poster presented at ESMO 2021 investigating the effects of PD-1 inhibition in smokers versus non-smokers in patients with non-squamous non-small cell lung cancer (NSCLC).
Reading
17 Sep 2021

k)MUEr j#9~9L39n 3A 1ruJ N*Nx @K 1 V|o\+~|i GcGvGJ@J Z- -ujO}KjY y&4 [N,N Vds#Z3V Oe e&et]1&D((] :Kd= 8_= {oi+% 2 1VSMk|VrIt_cd {QYpp (pG^@?@G0vwi# Fb`9 G;r{GH;rlT[Z B+ 3)rKm+)r/NSX xxsIB ?\ s4r|j6rl KH}F QhQuyq#_Kh#y 5a5|@I!GG 6|,, LKiY 61_6_o TbmMmM%%. `N oK\o$Z\_ r7F ;5I5 WX=g|[W, ^LS jsO u## -\55H-sHJ +DIc+gIt+ oy5y#v[I Mh Ne@-V-e}Ta[s |oa4 fjesh~je:zf].

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close